A61P 11/00
Drugs for disorders of the respiratory system
A61P11/00 (Drugs for disorders of the respiratory system) appears on 31,962 US grants and 47,610 published applications in this corpus.
Search patents in A61P- Granted patents
- 31,962
- Published applications
- 47,610
- Assignees
- 9,824
- Inventors
- 63,458
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 18 | 0 |
| 1977 | 24 | 0 |
| 1978 | 18 | 0 |
| 1979 | 21 | 0 |
| 1980 | 26 | 0 |
| 1981 | 32 | 0 |
| 1982 | 32 | 0 |
| 1983 | 41 | 0 |
| 1984 | 52 | 0 |
| 1985 | 52 | 0 |
| 1986 | 85 | 0 |
| 1987 | 84 | 0 |
| 1988 | 78 | 0 |
| 1989 | 102 | 0 |
| 1990 | 96 | 0 |
| 1991 | 103 | 0 |
| 1992 | 108 | 0 |
| 1993 | 111 | 0 |
| 1994 | 135 | 0 |
| 1995 | 180 | 0 |
| 1996 | 171 | 0 |
| 1997 | 264 | 0 |
| 1998 | 339 | 0 |
| 1999 | 440 | 0 |
| 2000 | 483 | 0 |
| 2001 | 594 | 167 |
| 2002 | 662 | 906 |
| 2003 | 685 | 1524 |
| 2004 | 550 | 2009 |
| 2005 | 621 | 2015 |
| 2006 | 790 | 1980 |
| 2007 | 867 | 2155 |
| 2008 | 968 | 2411 |
| 2009 | 1139 | 2788 |
| 2010 | 1496 | 3111 |
| 2011 | 1622 | 2862 |
| 2012 | 1866 | 2777 |
| 2013 | 2045 | 2234 |
| 2014 | 1950 | 2379 |
| 2015 | 1729 | 2250 |
| 2016 | 1593 | 2187 |
| 2017 | 1645 | 1976 |
| 2018 | 1423 | 1831 |
| 2019 | 1373 | 1692 |
| 2020 | 1204 | 1553 |
| 2021 | 1013 | 1365 |
| 2022 | 766 | 1223 |
| 2023 | 615 | 1497 |
| 2024 | 614 | 1191 |
| 2025 | 623 | 948 |
| 2026 | 414 | 579 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Prevention of viral transmission through feed6 Oct 2026US 12,751,931 B2Dsm IP Assets B.V.
- Pulmonary arterial compliance with inhaled nitric oxide (iNO) treatment6 Oct 2026US 12,751,968 B2Mallinckrodt Pharmaceuticals Ireland Limited
- Nanosuspension formulation for treatment of pulmonary fibrosis29 Sep 2026US 12,746,210 B2Federal University of Rio De Janeiro
- Method of treating SCLC and managing neutropenia29 Sep 2026US 12,746,240 B2Pharma Mar, S. A.
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Combination therapy for pulmonary hypertension8 Oct 2026US 2026/0306461 A1Vivus, Inc.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Methods and compositions for treating inflammatory and fibrotic pulmonary disorders8 Oct 2026US 2026/0306493 A1Board of Regents, The University of Texas System
- Fucosylated mammalian milk oligosaccharide for use in the prevention or treatment of pneumonia8 Oct 2026US 2026/0306521 A1Inbiose N.V.
Most cited
By later US patents
- (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses1,031US 7,094,916 B2Wisconsin Alumni Research Foundation · 2006
- Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer732US 4,496,689 AMiles Laboratories, Inc. · 1985
- Controlled release powder and process for its preparation660US 5,354,556 AElan Corporation, plc · 1994
- Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension648US 5,674,533 ARecordati S.A., Chemical and Pharmaceutical Company · 1997
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003